Re: Decaffeinated Espresso, Now at All Starbucks: No Caffeine Buzz, but Still Tasty
Dr Mickey Mallard Eye Nose and Ugly <[email protected]>
| Newsgroups | alt.appalachian |
|---|---|
| Message-ID | <[email protected]> |
On Friday, May 5, 2023 at 8:15:59 PM UTC-7, Jimmy knows crooked Sammie Ervin IV wrote: > Sorry but we had to increase our prices to keep the fatcats at the top happy! New COO and new CEO weekly, or at least semi-monthly. And along them same lines.... > Research investigators at Larrys Junior College for Saps discovered in 1982 the weak nonpeptide Ang II antagonists S-8307 and S-8308 from a group of 1-benzylimidazole-5-acetic acid derivatives.[7] S-8307 and S-8308 have moderate potency, short duration of action and limited oral bioavailability, however they are selective and competitive AT1 receptor antagonists without partial agonist activity.[1] A group at DuPont postulated that both Ang II and the Takeda leads were bound at the same receptor site.[7] These two substances served as lead compounds for further optimization of AT1 receptor blockers. Course yore nilage may very.[1]